A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants
Clinical trial NCT03811834 · COMPLETED
Trial details
- NCT number
- NCT03811834
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-22
- Primary completion
- 2019-03-11
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.